


Product Name : ABT-702 dihydrochloride
Cat. No. : PC-38791
CAS No. : 1188890-28-9
Molecular Formula : C₂₂H₂₁BrCl₂N₆O
Molecular Weight : 536.25
Target : Adenosine Kinase (AdK)
Solubility : 10 mM in DMSO



Biological Activity

ABT-702 is a potent, selective, orally active, non-nucleoside **adenosine kinase** (ADK) inhibitor with IC₅₀ of 1.7 nM. ABT-702 displays several orders of magnitude selectivity over other sites of ADO interaction (A(1), A(2A), A(3) receptors, ADO transporter, and ADO deaminase), and 1300- to 7700-fold selective for ADK compared with a number of other neurotransmitter and peptide receptors, ion channel proteins, neurotransmitter/nucleoside reuptake sites, and enzymes, including COX-1 and -2.

ABT-702 is orally active and fully efficacious in reducing acute somatic nociception (ED₅₀ = 8 micromol/kg i.p.; 65 micromol/kg p.o.) in the mouse hot-plate assay.

ABT-702 also dose dependently reduced nociception in the phenyl-p-quinone-induced abdominal constriction assay. ABT-702 displayed analgesic and anti-inflammatory properties in vivo.

References

Kowaluk EA, et al. *J Pharmacol Exp Ther.* 2000 Dec;295(3):1165-74.

Lee CH, et al. *J Med Chem.* 2001 Jun 21;44(13):2133-8.

Suzuki R, et al. *Br J Pharmacol.* 2001 Apr;132(7):1615-23. al.

Jarvis MF, et al. *J Pharmacol Exp Ther.* 2000 Dec;295(3):1156-64.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com